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Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban,
apixaban, edoxaban) have been introduced in several clinical indications. Although NOACs have a favourable benefit-risk
profile and can be used without routine laboratory monitoring, they are associatedeas any anticoagulantewith a risk of
bleeding. In addition, treatment may need to be interrupted in patients who need surgery or other procedures. The
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646 - Eikelboom et al.update on the management of NOAC-treated patients who experience a bleeding episode or require an urgent procedure.
Recent advances in the development of targeted reversal agents are expected to help streamline the management of
NOAC-treated patients in whom rapid reversal of anticoagulation is required.
Keywords: anticoagulants; coagulation monitoring; emergencies; haemorrhage; reversalEditor’s key points
 Current recommendations for the management of
bleeding and emergency procedures in patients treated
with NOACs are based on expert opinion and limited
clinical experience.
 When a patient on NOAC treatment presents for
emergency care, co-morbidities (including renal
impairment) and concomitant treatments associated
with increased bleeding should be identified;
measuring the anticoagulant effect of NOACs may be
helpful.
 Currently available therapeutic options include non-
specific pro-haemostatic agents, therapies aimed at
reducing drug exposure, and the specific reversal agent
idarucizumab, targeted at dabigatran.
Non-vitamin K antagonist oral anticoagulants (NOACs), also
referred to as direct oral anticoagulants, have been developed
as direct and specific inhibitors of single activated coagulation
factors.1,2 Two classes of agents that inhibit thrombin (dabi-
gatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have
been introduced in several clinical indications. Although
NOACs have a favourable benefit-risk profile, they are
associatedeas any anticoagulantewith a risk of bleeding. In
addition, treatment may need to be interrupted in patients
who need surgery or other procedures.
The objective of this article, developed by a multidisci-
plinary panel of experts in thrombosis and haemostasis, is to
provide an update on the management of NOAC-treated pa-
tients who experience a bleeding episode or require an urgent
procedure.Pharmacological characteristics and current
indications of NOACs
NOACs carry several advantages over vitamin K antagonists: a
more rapid onset and offset of action, a lower propensity for
food and drug interactions, and a predictable anticoagulant
effect that allows fixed-dose administration without routineTable 1 Effect of renal function on estimated half-lives of NOACs (fr
Dabigatran (h) Rivar
CrCl >80 ml min1 12e17 5e9
CrCl 50e80 ml min1 ~17 ~8.7
CrCl 30e50 ml min1 ~19 ~9.0
CrCl 15e30 ml min1 ~28 ~9.5
CrCl 15 ml min1 ‒ ‒coagulation monitoring.2 Their elimination half-lives in pa-
tients with a normal renal function are as follows: 14e17 h
(dabigatran), 7e11 h (rivaroxaban), 8e14 h (apixaban), and
5e11 h (edoxaban).2 About 80%, 50%, 33%, and 27% of dabiga-
tran, edoxaban, rivaroxaban, and apixaban, respectively, are
cleared unchanged via the kidneys.2
The direct thrombin inhibitor dabigatran and the direct
factor Xa inhibitors rivaroxaban, apixaban, and edoxaban
have received regulatory approval for the following clinical
indications: prevention of venous thrombosis after major or-
thopaedic surgery, prevention of stroke and systemic embo-
lism in patients with non-valvular atrial fibrillation (NVAF),
and treatment and secondary prevention of symptomatic
venous thrombosis. In addition, rivaroxaban is approved in
Europe for secondary prevention after an acute coronary
syndrome.Information needed for emergency care in
patients on NOACs
When a patient is known or suspected to be on NOAC treat-
ment presents for emergency care, careful medical history
taking is required to determine which NOAC, if any, is taken,
which dose regimen is used, and when the last dose was taken
(i.e. whether the drug level is pre- or post-peak).3 It is also
essential to identify co-morbidities and concomitant treat-
ments associated with an increased risk of bleeding. As the
half-lives of NOACs are influenced by renal function (see
Table 1)3 and patients with renal failure will be at increased
risk of bleeding complications as a result of the faulty renal
elimination, assessment of creatinine clearance is important
to evaluate when restoration of haemostasis can be expected
after cessation of NOAC treatment. Measuring the anticoagu-
lant effect of NOACs may also be helpful to guide emergency
care.Effect of NOACs on coagulation tests
Non-specific coagulation tests include the prothrombin time
(PT), the activated partial thromboplastin time (aPTT)
and point-of-care coagulation tests such as rotationalom Heidbuchel and colleagues3). CrCl, creatinine clearance
oxaban (h) Apixaban (h) Edoxaban (h)
12 10e14
~14.6 ~8.6
~17.6 ~9.4
~17.3 ~16.9
‒ ‒
C
T
,
cl
o
tt
in
g
x
im
u
m
cl
o
t
r -r
e
sp
o
n
se
e
st
)
, ,
:
,
Emergency care of NOAC-treated patients - 647thromboelastometry (ROTEM™) and thromboelastography
(TEG®). In contrast, specific assays provide information on the
effect of anticoagulants on individual coagulation factors. The
effect of NOACs on coagulation tests is summarized in
Table 2.4l
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eDirect thrombin inhibitor (dabigatran)
PT and the international normalized ratio are not appropriate
tests to assess the anticoagulant effect of dabigatran.5 The
aPTTmay be helpful to detect the presence of the drug (if other
causes of an elevated aPTT are excluded), but it cannot be used
to quantify the anticoagulant effect of dabigatran, especially at
high plasma levels.5 A normal aPTT does not always exclude
the presence of clinically important levels of dabigatran,
particularly when a relatively insensitive reagent is used.6,7
Point-of-care viscoelastic coagulation tests such as TEG8e10
or ROTEM11e13 may provide a quick and reliable assessment
of the anticoagulant effect of dabigatran. However, clinical
studies are warranted to evaluate the benefits and limitations
of viscoelastic coagulation tests in the acute care setting.14
Thrombin time (TT) is useful for detecting minimal dabi-
gatran levels; a normal TT excludes the presence of clinically
important levels of dabigatran.6 The dilute thrombin time
(dTT) performed with dabigatran calibrators is suitable for
determining the anticoagulant activity and calculating plasma
levels of dabigatran above the lower limit of detection (30e45
ng ml1).6,15,16 The ecarin clotting time (ECT) and the ecarin
chromogenic assay are closely and linearly correlated with
dabigatran plasma levels even at very low levels.5,16 However,
these tests are hampered by lack of standardization and
limited availability.17 The development of commercial kits is
expected to improve the availability and ease of use of these
tests.ct
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eDirect factor Xa inhibitors (rivaroxaban, apixaban, and
edoxaban)
The PT is generally increased in response to factor Xa inhibitor
treatment, but its sensitivity is much higher for edoxaban and
rivaroxaban than for apixaban.18e20 Large variations are
observed according to the thromboplastin reagent used, and a
normal PT does not exclude the presence of the drugs at
clinically relevant levels. Although the aPTTmay be prolonged
in the presence of direct factor Xa inhibitors, its sensitivity is
insufficient to exclude the presence of clinically relevant drug
levels.7,20 TEG8 and (modified) ROTEM13,21,22 assays might
permit rapid point-of-care determination of the anticoagulant
effect of rivaroxaban or apixaban.
Determination of the anti-factor Xa activity is the preferred
test for all direct factor Xa inhibitors. However, this test is not
routinely available in all laboratories, and it needs to be cali-
brated specifically for these drugs.23 Chromogenic anti-factor
Xa assays with calibration for the specific agent are available
in specialized laboratories, but turnaround times may pre-
clude their use in emergency situations.24T
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(mTherapeutic options for NOAC reversal or
removal
Therapeutic options for reversing the anticoagulant effect of
NOACs include non-specific prohaemostatic agents, therapies
aimed at reducing drug exposure, and reversal agents targeted
at dabigatran (idarucizumab), direct factor Xa inhibitors
648 - Eikelboom et al.(andexanet alfa), and both NOACs and heparin-based antico-
agulants (ciraparantag).Non-specific prohaemostatic agents
The efficacy and safety of non-specific prohaemostatic agents
in restoring haemostasis in patients treated with NOACs have
not been evaluated in clinical studies. At present, the evidence
supporting their use is limited to case reports or series, studies
in healthy human volunteers, animal models, and in vitro ex-
periments, which all carry important limitations.25Fresh frozen plasma
Fresh frozen plasma (FFP) is obtained by freezing plasma that
is removed from a whole blood donation or collected by
apheresis. Plasma transfusion is associated with significant
risks, including circulatory overload, allergic reactions,
transfusion-related acute lung injury, and potential for
transmission of blood-borne infections.26 Because of the likely
need to use large volumes to overcome the inhibition of
thrombin or factor Xa, FFP is not recommended to rapidly
reverse the anticoagulant effect of NOACs.27,28Non-activated prothrombin complex concentrates
Prothrombin complex concentrates (PCCs) are highly purified
concentrates of vitamin K-dependent coagulation factors
prepared from pooled normal plasma (see Table 3).29 All PCCs
undergo a viral inactivation procedure. The level of clotting
factors is approximately 25 times higher than in plasma,
allowing rapid factor substitution with small volumes.30 PCCs
can be administered rapidly, without cross-matching, and are
not associated with risks of circulatory overload and acute
lung injury.29,31 PCCs have been associated with a low (1.4%)
but non-negligible risk of thromboembolic adverse events.32
The evidence for the use of PCCs in restoring haemostasis
in patients treated with NOACs has been reviewed
recently.33,34 Preclinical and healthy volunteer studies suggest
that non-activated PCCs may be helpful in this setting, but the
efficacy of different PCC preparations appears to vary and
there is a lack of correlation between the effects of PCCs on
haemostasis and their influence on coagulation tests. Rapid
reversal of coagulopathy after administration of a 4-factor PCC
was reported in a dabigatran-treated elderly patient present-
ing with severe gastrointestinal haemorrhage.35 In a patient
with life-threatening rectal bleeding on dabigatran treatment,
bleeding cessation was achieved after administration of two
doses of 4-factor PCC, whilst coagulation parameters
remained abnormal.36 In an apixaban-treated patient with
severe traumatic bleeding refractory to blood product support,
4-factor PCC failed to restore haemostasis.37 Favourable out-
comes after 4-factor PCC administration were reported in six
of 18 patients with intracranial haemorrhage who were
receiving rivaroxaban or apixaban.38
Administration of non-activated PCCs may be considered
in clinical situations where urgent reversal of NOACs is
required.27,34 As a result of the lack of clinical data, there is
currently no consensus regarding PCC dosing.33 An initial dose
of 50 IU kg1, followed by an additional dose of 25 IU kg1 if
clinically indicated, has been suggested.3 Considering the
strong thrombin generating push induced by PCC and the pre-
existing thrombogenic diathesis, careful titration of up to25 IU kg1, with repeated doses in cases of ongoing bleeding,
has also been proposed.27Activated PCC
Activated PCC (aPCC), or factor VIII inhibitor bypassing agent
(FEIBA, Baxter, Deerfield, IL, USA), was developed as a pro-
haemostatic agent for the management of patients with hae-
mophilia and inhibitors to coagulation factors VIII or IX.26
aPCC is a surface-activated PCC containing small quantities
of FIXa, FXa, and thrombin, and larger amounts of FVIIa. A
vapour heat treatment procedure is used for inactivation of
blood-borne viruses.39 Pharmacovigilance assessments indi-
cate that the incidence of thromboembolic events after
administration of FEIBA in patients with haemophilia is very
low.40 However, the safety profile of FEIBA in non-
haemophiliac patients with risk factors for thrombosis is
unknown.
Successful management of dabigatran-associated life-
threatening bleeding episodes with aPCC was reported in one
patient41 and in a series of four patients.42 aPCC was reported
to correct all thrombin generation parameters in vitro in
plasma from healthy volunteers who were taking rivaroxaban
or apixaban, and to reduce blood loss in animal models after
administration of rivaroxaban or edoxaban.43 From the
perspective of practicability and safety, aPCC has the disad-
vantage of not being used routinely in perioperative medicine
whilst PCC is commonly included in treatment algorithms.Recombinant activated factor VII
Recombinant activated factor VII (rFVIIa; NovoSeven, Novo
Nordisk, Bagsvaerd, Denmark) is a recombinant protein origi-
nally developed to treat or prevent bleeding in patients with
haemophilia A or Bwith inhibitors to factor VIII or IX.44 Clinical
trials and post-marketing data indicate that the incidence of
thromboembolic events after administration of rFVIIa in
approved indications is low.45 In randomized controlled trials
evaluating rFVIIa in off-label indications, the risk of arterial
thrombosis was significantly increased compared with pla-
cebo (5.5% vs 3.2%).46
In animal models, rFVIIa improved some haemostasis-
related parameters but failed to reduce blood loss after
administration of dabigatran or rivaroxaban.47e50 In a cell-
based model of haemostasis, rFVIIa improved parameters of
thrombin generation in the presence of therapeutic but not
supratherapeutic dabigatran levels.51 Considering the strong
thrombin generating push induced by rFVIIa and the pre-
existing thrombogenic diathesis, rFVIIa should only be regar-
ded as a last-resort option in life- or organ-threatening
bleeding, especially in patients with acute ischaemic events.Antifibrinolytic agents
Antifibrinolytic agents include tranexamic acid and epsilon-
aminocaproic acid, which preserve haemostasis through
plasmin inhibition, and aprotinin, which inhibits multiple
serine proteases. Antifibrinolytics have been shown to reduce
bleeding and transfusion requirements in the perioperative
setting.52 In a large randomized trial, tranexamic acid reduced
mortality in bleeding trauma patients.53 There are currently no
clinical data supporting the use of antifibrinolytic agents to
improve haemostasis in patients treated with a NOAC; how-
ever, they may be used as adjuvant therapy in patients with
Table 3 Coagulation factor content of the most commonly used non-activated prothrombin complex concentrates (adapted from
Grottke and Levy29). N/A, information not available
Product Availability Coagulation factors (IU ml¡1)
Factor II Factor VII Factor IX Factor X
3-factor PCCs
Prothromplex TIM 3 (Baxter) Europe 25 N/A 25 25
Cofact/PPSB SD (Sanquin/CAF) Europe 15 5 20 15
Bebulin VH (Baxter) USA 24e38 <5 24e38 24e38
Profilnine SD (Grifols) USA 1.5 IU/IU factor IX 0.35 IU/IU factor IX 100 U 1 IU/IU factor IX
4-factor PCCs
Beriplex P/N, Confidex or
Kcentra (CSL Behring)
Europe, Canada, USA 20e48 10e25 20e31 22e60
Octaplex (Octapharma) Europe, Canada 14e38 9e24 25 18e30
Prothromplex Total/S-TIM 5 (Baxter) Europe 30 25 30 30
Emergency care of NOAC-treated patients - 649NOAC-associated bleeding.3,54 Antifibrinolytics should not be
used in patients with prior acute coronary syndromes or ce-
rebral ischaemic events because of the risk of secondary
thromboembolic events.Therapies aimed at reducing drug exposure
Therapies aimed at reducing drug exposure include measures
to reduce drug absorption and to remove the drug from the
blood.Activated charcoal
Activated charcoal is a processed form of carbon that can bind
to oral drugs and reduce absorption from the gastrointestinal
tract. In vitro data indicate that dabigatran etexilate can be
successfully adsorbed by activated charcoal therapy5 and a
study in healthy volunteers showed that administration of
activated charcoal up to 6 h after a single 20-mg dose of
apixaban reduced apixaban exposure and facilitated drug
elimination.55 A woman who presented to the emergency
department after ingesting 11.25 g of dabigatran in a suicide
attempt was successfully managed with gastric lavage and
activated charcoal therapy.56 The use of activated charcoal to
reduce absorption may be considered in case of a recent
overdose with any NOAC, using a standard dosing scheme of
30e50 g for adults.3 The contraindications and side effects of
charcoal should be considered.Haemodialysis
Dabigatran can be removed from the circulation through
dialysis because of its relatively low plasma protein binding
(~35%). In patients with end-stage renal disease, 50e60% of
active dabigatran was removed after 4 h of haemodialysis.57
Haemo(dia)filtration is suggested to be efficacious in
removing dabigatran after an application of more than 4 h.27 A
systemic review identified 35 cases of dabigatran-associated
bleeding in which haemodialysis was used for dabigatran
removal and the effect of haemodialysis on bleeding was re-
ported.58 There were significant reductions in dabigatran
levels after haemodialysis, but a rebound of dabigatran level
was observed in some patients after cessation of dialysis.
Haemostasis was achieved in 24 patients and 10 patients died
as a result of bleeding.Haemodialysis may be considered in dabigatran-treated
patients who present with life-threatening bleeding or
require emergency surgery, particularly in case of renal
impairment. Disadvantages include the long duration until
removal of dabigatran by renal replacement therapy, compli-
cations associated with extracorporeal circulation and anti-
coagulation in the critical event of severe or massive bleeding,
and the requirement of intensive care resources.
As rivaroxaban and apixaban are highly protein bound, it is
unlikely that they can be removed by haemodialysis.26 In pa-
tients with end-stage renal disease treated with edoxaban,
haemodialysis resulted in a minor decrease in drug levels,
suggesting that haemodialysis is not an effective option for
removal of edoxaban from the blood.59Targeted reversal agents
Three targeted reversal agents are currently being evaluated:
idarucizumab, a humanized murine monoclonal antibody
fragment directed specifically at dabigatran; andexanet alfa, a
recombinant modified decoy factor Xa that binds to factor Xa
inhibitors; and ciraparantag, a small molecule that binds to
factor Xa and thrombin inhibitors and to heparin-based anti-
coagulants through charge interaction.60Idarucizumab
Idarucizumab (Praxbind®, Boehringer Ingelheim, Ingelheim,
Germany) is a humanized Fab antibody fragment that binds
specifically and with high affinity to dabigatran.61 In healthy
volunteers, idarucizumab administered alone as a 1-h or 5-
min infusion was safe and well tolerated, and had no effect
on coagulation parameters.62,63When administered in healthy
volunteers treated with dabigatran etexilate, idarucizumab
immediately reversed dabigatran-induced anticoagulation in
a dose-dependent manner, with a complete and sustained
effect over 72 h for doses of 2 g or greater.64 Rapid and sus-
tained reversal of dabigatran-induced anticoagulation was
also observed after administration of idarucizumab (5 g or
22.5 g) in male and female healthy volunteers who were
middle-aged (45e64 yr) or elderly (65e80 yr), and in patients
with mild or moderate renal impairment (creatinine clearance
of 60 to <90 and 30 to <60 ml min1, respectively).65 Effective
dabigatran anticoagulation can be re-established 24 h after
administration of idarucizumab.66
650 - Eikelboom et al.The efficacy and safety of idarucizumab (5 g administered
as two 50 ml bolus infusions no more than 15 min apart) for
the reversal of the anticoagulant effects of dabigatran in pa-
tients with uncontrollable or life-threatening bleeding and in
those requiring an urgent surgical or invasive procedure have
been investigated in the Study of the REVERSal Effects of
idarucizumab in patients on Active Dabigatran (RE-VERSE
AD™), a global Phase 3 prospective cohort study.67 The full
cohort analysis included 503 patients (301 with serious
bleeding and 202 requiring an urgent procedure). Amongst 461
patients with an elevated dTT or ECT at baseline, the median
maximum percentage reversal was 100% [95% confidence in-
terval (CI), 100e100]. After administration of idarucizumab,
levels of unbound dabigatran decreased to 20 ngml1 or below
in all but three of the patients who could be assessed; within
24 h after idarucizumab administration, dabigatran levels
above this threshold were observed in 23% of the assessed
patients, mainly after 12 h. Amongst 203 patients with serious
bleeding for whom the time to cessation of bleeding could be
ascertained, 134 (67.7%) had confirmed bleeding cessation
within 24 h and median time to haemostasis was 2.5 h.
Amongst the 197 patients who underwent an urgent proced-
ure, normal haemostasis was reported in 184 (93.4%).
Thrombotic events were reported in 24 patients (4.8%) within
30 days after treatment.
The pharmacology of idarucizumab and clinical data on its
use to reverse the anticoagulant activity of dabigatran have
been reviewed recently.68 Idarucizumab has been approved by
the United States Food and Drug Administration and the
European Commission for use in adult patients treated with
dabigatran etexilate when rapid reversal of its anticoagulant
effects is required: (i) for emergency surgery/urgentTable 4 Practical use of idarucizumab for dabigatran reversal
Presentation Two vials containing each 2.5 of id
Mode of administration I.V. administration as two consecu
Dosing The recommended dose is 5 g (2
Administration of a second dose
No dose adjustment is required
those aged 65 yr and above
Restarting antithrombotic
therapy after idarucizumab
administration
Treatment with dabigatran etexila
administration of idarucizumab
been achieved
Absence of antithrombotic thera
disease or condition
Precautions for use Hypersensitivity
The risk of using idarucizumab i
any of the excipients should be
anaphylactic reaction or other s
should be discontinued immedia
Hereditary fructose intolerance
The recommended dose of idaru
hereditary fructose intolerance,
serious adverse events and deat
against the potential benefit in s
medical care during exposure an
Urinary protein testing I.V. administration of idarucizuma
protein overflow. This transient
taken into account for urine test
Interactions with other drugs No interactions with volume expa
activated prothrombin complex
than dabigatran etexilate have bprocedures; and (ii) in life-threatening or uncontrolled
bleeding. Information on the practical use of idarucizumab is
provided in Table 4.Andexanet alfa
Andexanet alfa (AndexXa®, Portola Pharmaceuticals, South
San Francisco, CA, USA) is a modified, human recombinant
factor Xa that is catalytically inactive but retains high-affinity
binding to direct factor Xa inhibitors and heparin-
antithrombin III complexes.69 The safety and efficacy of
andexanet alfa in reversing the anticoagulant effects of apix-
aban and rivaroxaban in healthy older volunteers has been
evaluated in two parallel randomized, double-blind, placebo-
controlled Andexanet Alfa a Novel Antidote to the Anticoag-
ulant Effects of fXA Inhibitors (ANNEXA) Phase III studies.70 In
the ANNEXA-A study, participants received 5 mg of apixaban
twice daily for 3.5 days and andexanet alfa was administered
i.v. as a 400-mg bolus or as a 400-mg bolus followed by a
continuous infusion of 4 mg min1 for 120 min. In the
ANNEXA-R study, participants received 20 mg of rivaroxaban
once daily for 4 days and andexanet alfa was administered i.v.
as an 800-mg bolus or as an 800-mg bolus followed by a
continuous infusion of 8mgmin1 for 120min. Andexanet alfa
rapidly and completely reversed the anticoagulant effect of
rivaroxaban and apixaban, respectively, with amaximal effect
within 2e5min after administration of the bolus. Reversal was
sustained after administration of a bolus plus a continuous
infusion, but not after administration of a bolus alone. Anti-Xa
activity returned to placebo levels within 1e3 h after the
administration of the infusion. No serious adverse or throm-
botic events were reported.arucizumab in a 50 ml solution
tive infusions over 5e10 min each or as a bolus injection
2.5 g)
of 5 g may be considered if clinically indicated
in patients with renal impairment or hepatic impairment and
te or other antithrombotic agents, can be re-initiated 24 h after
if the patient is clinically stable and adequate haemostasis has
py exposes patients to the thrombotic risk of their underlying
n patients with known hypersensitivity to idarucizumab or to
weighed cautiously against the potential benefit. If an
erious allergic reaction occurs, administration of idarucizumab
tely and appropriate therapy initiated
cizumab contains 4 g sorbitol as an excipient. In patients with
parenteral administration of sorbitol has been associated with
h. The risk of treatment with idarucizumab should be weighed
uch patients. If idarucizumab is administered, intensified
d within 24 h of exposure is required
b causes transient proteinuria as a physiologic reaction to renal
proteinuria is not indicative of renal damage, which should be
ing
nders, coagulation factor concentrates (activated and non-
concentrates, recombinant factor VIIa), or anticoagulants other
een reported
Emergency care of NOAC-treated patients - 651The prospective, open-label, single-group ANNEXA-4 study
is currently evaluating the efficacy and safety of
andexanet alfa in patients with factor Xa inhibitor-associated
acute major bleeding. The first 67 patients enrolled in the
study have been included in an interim report.71
Andexanet alfa was administered as a bolus (15e30 min) fol-
lowed by a 2-h infusion. A bolus dose of 400 mg and an infu-
sion dose of 480 mg were used for patients on apixaban or
known to have taken rivaroxaban more than 7 h before
administration of andexanet alfa, whereas patients on enox-
aparin or edoxaban and those who had taken rivaroxaban 7 h
or less before administration of andexanet alfa or at an un-
known time received a bolus dose of 800 mg and an infusion
dose of 960 mg. The two co-primary efficacy outcomes were
the percent change in anti-factor Xa activity and the rate of
excellent or good haemostatic efficacy 12 h after the infusion.
Median anti-factor Xa activity decreased by 89% (95% CI,
58e94) amongst rivaroxaban-treated patients and by 93% (95%
CI, 87e94) amongst apixaban-treated patients. Clinical hae-
mostasis 12 h after the infusion was rated as excellent or good
in 79% (95% CI, 64e89) of the 47 patients included in the effi-
cacy analysis. Thrombotic events occurred in 12 patients (18%)
during the 30-day follow-up.Ciraparantag
Ciraparantag (Perosphere Pharmaceuticals, Danbury, CT, USA)
is a small, synthetic, water-soluble, cationic molecule which
reverses unfractionated heparin, low-molecular-weightFig 1. Management of bleeding in patients treated with non-vitamin
thrombin complex concentrate; PCC, prothrombin complex concentraheparin and fondaparinux through non-covalent hydrogen
binding and charge‒charge interactions, and NOACs through
non-covalent hydrogen binding.72 In thromboelastographic
studies and animal models, ciraparantag was shown to
reverse the anticoagulant effect of all NOACs. In healthy vol-
unteers, a single i.v. dose of ciraparantag within 3 h after
administration of 60 mg of edoxaban decreased whole-blood
clotting time to within 10% above the baseline value in 10
min or less.72Management of bleeding in patients treated
with NOACs
In the absence of high-quality evidence from randomized tri-
als to guide clinical practice, current recommendations for the
management of bleeding in patients treated with NOACs are
based on expert opinion and limited clinical experience (Fig. 1).
The European Heart Rhythm Association has published a
practical guide on the use of NOACs in patients with NVAF,
updated in 2015, which includes a section on bleeding man-
agement.3 Practical guidance has also been provided by
several expert groups.27,54,73e76
The management of bleeding in patients on NOAC therapy
should be tailored according to the severity and location of the
haemorrhage. Medical history taking is required to identify co-
morbidities and concomitant treatments associated with an
increased bleeding risk and to assess which NOAC is taken,
which dose regimen is used, and when the last dose was
taken. A renal function test is important to evaluate whenK antagonist oral anticoagulants (NOACs). aPCC, activated pro-
te; recombinant activated factor, rFVIIa.
Fig 2. Management of non-vitamin K antagonist oral anticoagulant (NOAC)-treated patients who require an emergency surgical or invasive procedure. aPCC, activated prothrombin complex
concentrate; PCC, prothrombin complex concentrate; recombinant activated factor, rFVIIa.
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Emergency care of NOAC-treated patients - 653restoration of haemostasis can be expected after cessation of
treatment. Adequate diuresis should be maintained to facili-
tate renal elimination of the NOAC.
In patients with mild bleeding, treatment discontinuation,
local haemostatic measures and clinical observation may be
sufficient. In case of ongoing, severe bleeding, coagulation
monitoring is helpful to assess the anticoagulant effect of the
drug and potentially secondary bleeding disorders. Specific
tests should not delay the application of supporting measures
such as fluid resuscitation, red blood cell transfusion, platelet
transfusion, antifibrinolytic agents, and invasive haemostatic
methods (surgical and radiological/endovascular in-
terventions). Hypothermia, acidosis, and hypocalcaemia
should be avoided or corrected if present. Activated oral char-
coalmay be administered to reduce drug absorptionwithin 2e4
h after the last NOAC dose was taken. NOAC reversal or
removal cannot be recommended for all patients with
moderate-to-severe bleeding, but may be considered based on
clinical judgement and interdisciplinary consultation.
In case of uncontrolled, organ-threatening or life-
threatening bleeding, NOAC reversal is recommended. In
dabigatran-treated patients, idarucizumab should be consid-
ered as the first-line option. In direct factor Xa inhibitor-treated
patients (and in dabigatran-treated patients if idarucizumab is
not available), administration of PCC (25 or 50 IU kg1, followed
by additional 25 IU kg1 doses in case of ongoing bleeding)
should be considered; alternatively, administration of aPCC (50
U kg1; maximum daily dose 200 U kg1) or rFVIIa (90 mg kg1)
may be considered. These therapeutic options should only be
used after a careful benefit/risk assessment. FFP should not be
used as a reversal agent unless no coagulation factor concen-
trate is available. Haemodialysis may be considered in
dabigatran-treated patients, particularly in case of impaired
renal function, if idarucizumab is not available. The roles of
andexanet alfa and ciraparantag in reversing the anticoagulant
activity of factor Xa inhibitors require further evaluation.Management of NOAC-treated patients who
require an urgent surgical or invasive
procedure
Many patients on long-term oral anticoagulation will at some
point require a surgical or invasive procedure (Fig. 2). One-
third of the patients enrolled in the ROCKET AF trial required
at least one treatment interruption, of whom 40% experienced
treatment interruption for a surgical or invasive procedure.77
In the RE-LY trial, 2% of the study participants underwent an
urgent surgical or invasive procedure.78 Amongst close to 2200
patients enrolled in the Dresden NOAC registry, 595 (27.3%)
underwent a total of 863 surgical or interventional procedures,
of which 10% were classified as major.79 Interventions asso-
ciated with a major bleeding risk include thoracic and
abdominal surgery, major orthopaedic surgery, transurethral
prostate resection, kidney and liver biopsy, or catheter abla-
tion of simple left-sided supraventricular tachycardia.3
Several working groups3,27,73e76 have provided guidance for
the management of NOAC-treated patients requiring urgent
procedures, and the European Society of Anaesthesiology has
published recommendations on regional anaesthesia and
antithrombotic therapy80 and the management of severe
perioperative bleeding.81
If an emergency intervention is required, assessment of
coagulation and renal function should be performed toevaluate the anticoagulant effect of the NOAC and its time of
elimination. The risk of bleeding associated with the type of
procedure, the patient’s condition, and the level of anticoag-
ulant activity have to be weighed against the risk of delaying
the procedure. If possible, interventions with a moderate-to-
high bleeding risk should be delayed by at least 24 h and, in
case of impaired renal elimination, up to 96 h. NOAC treat-
ment interruption is recommended in case of moderate or
high bleeding risk and may be considered in case of minor
bleeding risk (if treatment is not interrupted, the procedure
should be performed at trough level).
If the procedure cannot be delayed and the patient’s
coagulation status indicates a high risk of bleeding, NOAC
reversal should be considered before the procedure. In
dabigatran-treated patients, idarucizumab is the preferred
option. In direct factor Xa inhibitor-treated patients (and in
dabigatran-treated patients if idarucizumab is not available),
administration of PCC (alternatively, aPCC or rFVIIa) should be
considered (see the section on Management of bleeding in
patients treated with NOACs). In dabigatran-treated patients,
haemodialysis may be considered if the intervention can only
be postponed by less than 12 h and idarucizumab is not
available. If the estimated risk of bleeding is minor or mod-
erate, reversal agents may not be administered prophylacti-
cally but should be available in case abnormal bleeding occurs.Conclusion
The development of NOACs has opened a new era in the pre-
vention and treatment of thromboembolic events. Whilst the
favourable benefit-risk profile of NOACs is well recognized, the
lack of specific reversal agents has made the management of
some patients problematic. The availability of specific reversal
agents will provide further reassurance and is expected to help
streamline the management of NOAC-treated patients in
whom rapid reversal of anticoagulation is required. The
practical guidance provided in this article aims to help clini-
cians make appropriate use of available therapeutic options in
daily clinical practice.Authors’ contributions
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